<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00973336</url>
  </required_header>
  <id_info>
    <org_study_id>PHPT02_2008</org_study_id>
    <nct_id>NCT00973336</nct_id>
  </id_info>
  <brief_title>Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?</brief_title>
  <official_title>Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Successful Surgery in Patients Without Osteoporosis?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Hyperparathyroidism (pHPT) increases bone turnover and resorption and thus calcium
      efflux out of bone. After successful surgical treatment of pHPT, bone takes up calcium again
      which may result in secondary hyperparathyroidism or even &quot;hungry bone syndrome&quot;. Until today
      there are no studies about this problem helping to develop recommendations or guidelines how
      to prevent these symptoms.

      Study hypothesis: Calcium and vitamin D intake after surgery for PHPT protects the bone by
      keeping PTH in the normal range (less secondary, reactive hyperparathyroidism), prevents
      hungry bone- syndrome and improve bone-turnover markers (osteoporosis protection).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parathyroid hormone</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMD of lumbar spine, femoral neck and radius</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects calcium or vitamin D</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other biochemical markers of bone metabolism</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <condition>Bone Metabolism</condition>
  <arm_group>
    <arm_group_label>Calcium and vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment (control)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium and vitamin D</intervention_name>
    <description>1000mg calcium per day 800 IE vitamin D per day</description>
    <arm_group_label>Calcium and vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women

          -  Male patients

          -  Biochemically proven PHPT, PTX planned

          -  No evidence for osteoporosis

        Exclusion Criteria:

          -  Postoperative hypocalcemia needing substitution with calcium and vitamin D/
             1-25-OH-Vitamin D

          -  Cancer (lung, breast, prostatic, parathyroid cancer and thyroid carcinoma &gt;1cm)

          -  Persisting or recurrent PHPT (postoperative hypercalcemia)

          -  Four-gland hyperplasia

          -  Multiple endocrine neoplasia (MEN) or hereditary PHPT

          -  Familial hypercalciuric hypercalcaemia (Ca/creatinine ratio &lt; 0.01)

          -  Phenylketonuria

          -  Renal impairment (creatinine clearance &lt;30ml/h)

          -  Severe hepatic disorder

          -  Severe systemic disorder

          -  Thyroid dysfunction

          -  Immobilisation

          -  Intake of drugs with potential effects on BMD like glucocorticoids, lithium,
             estrogen-replacement therapy, selective Estrogen-receptor modulators (sERMs),
             bisphosphonates in the last three months

          -  Intake of drugs containing digoxin or digitoxin

          -  Known allergy against any component of the study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Niederle, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Department of Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philipp Riss, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>5621</phone_ext>
    <email>philipp.riss@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruno Niederle, Professor, MD</last_name>
    <phone>+43140400</phone>
    <phone_ext>6943</phone_ext>
    <email>chir-endokrin@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Riss, MD</last_name>
      <phone>+43140400</phone>
      <phone_ext>5621</phone_ext>
      <email>philipp.riss@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Philipp Riss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno Niederle, Prof., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reza Asari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Scheuba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Kerschan-Schindl, Prof., MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Pietschmann, Prof., MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Bieglmayer, Prof., PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin B Niederle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Philipp Riss</investigator_full_name>
    <investigator_title>Assistent Professor</investigator_title>
  </responsible_party>
  <keyword>postoperative follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

